Teewinot gets US patent for bioreactor used to make synthetic cannabinoid APIs
Teewinot Life Sciences has been granted a US patent for a bioreactor it uses to produce synthetic cannabinoids.
Teewinot Life Sciences has been granted a US patent for a bioreactor it uses to produce synthetic cannabinoids.
The EMA is recommending the suspension of several medicines after inspections revealed flawed studies at the India-based contract research organization (CRO), Semler Research Centre.